Polina Kaplan

2.0k total citations · 1 hit paper
9 papers, 331 citations indexed

About

Polina Kaplan is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Polina Kaplan has authored 9 papers receiving a total of 331 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 4 papers in Hematology. Recurrent topics in Polina Kaplan's work include Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Polina Kaplan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Polina Kaplan collaborates with scholars based in Poland, United Kingdom and United States. Polina Kaplan's co-authors include Gerardo Musuraca, Árpád Illés, Martin Šimkovič, Paolo Ghia, Małgorzata Wach, Daniel Lysák, Sean Dolan, Abraham Jacob, Wojciech Jurczak and Tomáš Kozák and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia & lymphoma.

In The Last Decade

Polina Kaplan

9 papers receiving 328 citations

Hit Papers

ASCEND: Phase III, Randomized Trial of Acalabrutinib Vers... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    2020 252 citations Paolo Ghia, Andrzej Pluta et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Polina Kaplan Poland 6 283 228 116 94 59 9 331
Laurie Musial United States 5 265 0.9× 219 1.0× 135 1.2× 93 1.0× 71 1.2× 8 350
Binsah George United States 4 257 0.9× 192 0.8× 106 0.9× 85 0.9× 48 0.8× 8 294
Talha Munir United Kingdom 5 331 1.2× 264 1.2× 97 0.8× 135 1.4× 42 0.7× 16 365
Francesca Yates United Kingdom 6 260 0.9× 204 0.9× 94 0.8× 88 0.9× 37 0.6× 11 278
Laura Wake United States 5 221 0.8× 186 0.8× 51 0.4× 102 1.1× 42 0.7× 17 270
Manuela A. Bergmann Germany 6 562 2.0× 502 2.2× 104 0.9× 239 2.5× 55 0.9× 11 592
Владимир Стругов Russia 4 466 1.6× 392 1.7× 124 1.1× 167 1.8× 63 1.1× 12 485
Iryna Kryachok Ukraine 8 127 0.4× 123 0.5× 36 0.3× 70 0.7× 64 1.1× 23 197
Geisler Ch Denmark 5 357 1.3× 291 1.3× 73 0.6× 186 2.0× 49 0.8× 6 388
Athanassios Zomas Greece 5 287 1.0× 248 1.1× 116 1.0× 121 1.3× 49 0.8× 6 355

Countries citing papers authored by Polina Kaplan

Since Specialization
Citations

This map shows the geographic impact of Polina Kaplan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Polina Kaplan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Polina Kaplan more than expected).

Fields of papers citing papers by Polina Kaplan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Polina Kaplan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Polina Kaplan. The network helps show where Polina Kaplan may publish in the future.

Co-authorship network of co-authors of Polina Kaplan

This figure shows the co-authorship network connecting the top 25 collaborators of Polina Kaplan. A scholar is included among the top collaborators of Polina Kaplan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Polina Kaplan. Polina Kaplan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 38(25). 2849–2861. 252 indexed citations breakdown →
2.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results. Clinical Lymphoma Myeloma & Leukemia. 20. S220–S221. 1 indexed citations
3.
Dimopoulos, Meletios Α., Sosana Delimpasi, Maryana Simonova, et al.. (2020). Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.. Journal of Clinical Oncology. 38(15_suppl). 8501–8501. 22 indexed citations
4.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.. Journal of Clinical Oncology. 38(15_suppl). 8015–8015. 5 indexed citations
5.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2019). Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. Clinical Lymphoma Myeloma & Leukemia. 19. S280–S281. 1 indexed citations
6.
7.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2019). Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. Hematological Oncology. 37(S2). 86–87. 21 indexed citations
8.
Österborg, Anders, Andrey Zaritskey, Sebastian Grosicki, et al.. (2016). Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 57(9). 2037–2046. 20 indexed citations
9.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laurie Musial Breakdown of academic impact, for papers by Binsah George Breakdown of academic impact, for papers by Talha Munir Breakdown of academic impact, for papers by Francesca Yates Breakdown of academic impact, for papers by Laura Wake Breakdown of academic impact, for papers by Manuela A. Bergmann Breakdown of academic impact, for papers by Владимир Стругов Breakdown of academic impact, for papers by Iryna Kryachok Breakdown of academic impact, for papers by Geisler Ch Breakdown of academic impact, for papers by Athanassios Zomas
Rankless by CCL
2026